ConductScience.org, home
Therapeutic developments in pancreatic cancer.
API referenceFor AI assistants

Paper · 37798442

Cited by277

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 375 citations.

1 to 20 of 277

Download this page as JSON
PMIDTitleJournalYearIn PapersSource
42,983,487Dual-organelle-coordinated sonodynamic nanoplatform amplifies immunogenic cell death to drive robust antitumor immunity in cold tumors.J Nanobiotechnology2026https://conductscience.org/library/papers/42983487PubMed
42,952,609Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.Front Immunol2026https://conductscience.org/library/papers/42952609PubMed
42,934,594Burdens of pancreatic cancer from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study.BMC Cancer2026https://conductscience.org/library/papers/42934594PubMed
42,892,656Difluoromethylornithine modulates mutant K-RAS signaling pathways in pancreatic cancer cells.Amino Acids2026https://conductscience.org/library/papers/42892656PubMed
42,873,463Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers.Curr Oncol Rep2026https://conductscience.org/library/papers/42873463PubMed
42,861,168Sialic Acid-Targeting Lectin-Conjugated Oxygen Nanosomes Alleviate Hypoxia and Promote Macrophage Activation in Pancreatic Cancer Cells.Int J Nanomedicine2026https://conductscience.org/library/papers/42861168PubMed
42,858,298MVB Maturation Responsive to KRASG12D/TP53R175H Co-mutations Fuels Extracellular Vesicle-hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis.J Extracell Vesicles2026https://conductscience.org/library/papers/42858298PubMed
42,856,962Super-Resolution MRI-Derived Tumor-Stroma Ratio Phenotyping for Prognostic and Therapeutic Stratification in Pancreatic Ductal Adenocarcinoma.MedComm (2020)2026https://conductscience.org/library/papers/42856962PubMed
42,844,287Deep learning CT signature for predicting early liver metastases in pancreatic ductal adenocarcinoma.Nat Commun2026https://conductscience.org/library/papers/42844287PubMed
42,797,417Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797417PubMed
42,761,119Integrated analysis of isorhamnetin-associated targets in chronic pancreatitis and pancreatic cancer: immune-infiltration associations and antitumor effects in pancreatic cancer cells.Front Immunol2026https://conductscience.org/library/papers/42761119PubMed
42,749,962Decoding neuro-tumor interactions in pancreatic cancer: mechanisms, immunosuppressive networks and therapeutic opportunities.Mol Biomed2026https://conductscience.org/library/papers/42749962PubMed
42,730,833Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology.Mol Biol Rep2026https://conductscience.org/library/papers/42730833PubMed
42,724,844Microplastics and nanoplastics-related genes signature predicts prognosis in pancreatic ductal adenocarcinoma and functional validation of interleukin 1 alpha.Transl Cancer Res2026https://conductscience.org/library/papers/42724844PubMed
42,687,049Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42687049PubMed
42,676,425Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer.Front Immunol2026https://conductscience.org/library/papers/42676425PubMed
42,662,135Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.Front Med (Lausanne)2026https://conductscience.org/library/papers/42662135PubMed
42,654,145Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma.Pharmaceutics2026https://conductscience.org/library/papers/42654145PubMed
42,651,818The Metabolic Rheostat Index Uncovers Pathway-Level Coordination, Immunosuppressive Microenvironment Remodeling, and Therapeutic Co-Vulnerabilities in Pancreatic Ductal Adenocarcinoma.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42651818PubMed
42,640,583Single-Cell Glycomics of the Pancreatic Tumor Microenvironment: Technologies, Glyco-Immune Checkpoints, and Tumor-Immune Communication.Adv Biol (Weinh)2026https://conductscience.org/library/papers/42640583PubMed

papers-2026-11-12-0.1.0

Next page

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/37798442/cited_by

API referenceFor AI assistants